Acquired inhibitors in malignant and nonmalignant disease states.
Acquired inhibitors against factor VIII:C (FVIII:C) arise in nonhemophilic patients who have many associated disease states, both malignant and benign. This review emphasizes knowledge of the association with malignant diseases and places particularly close attention on the hematologic malignancies, including plasma cell dyscrasias and lymphoproliferative disorders. Characteristics of postpartum inhibitors are examined, as well as the association of inhibitor with certain drugs and dermatologic conditions. Also discussed is the experience amassed by one center over the past decade in the treatment of patients with inhibitors against FVIII:C.
Hultin
M B
MB
Division of Hematology, State University of New York, Stony Brook.
D001323:Autoantibodies / Q000032:analysis* / Q000187:drug effects; D005169:Factor VIII / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000276:immunology*; D049590:Postpartum Period / Q000276:immunology*; D012871:Skin Diseases / Q000276:immunology*
D001323:Autoantibodies; D005169:Factor VIII